Loading...
IGMS logo

IGM Biosciences, Inc.NasdaqGS:IGMS Stock Report

Market Cap US$76.6m
Share Price
US$1.27
US$1.12
13.0% overvalued intrinsic discount
1Y-86.1%
7D0%
1D
Portfolio Value
​
View

IGM Biosciences, Inc.

NasdaqGS:IGMS Stock Report

Market Cap: US$76.6m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

IGM Biosciences (IGMS) Stock Overview

A biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. More details

IGMS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap ($77M)

Has less than 1 year of cash runway


IGMS Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

IGM Biosciences, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for IGM Biosciences
Historical stock prices
Current Share PriceUS$1.27
52 Week HighUS$22.50
52 Week LowUS$0.92
Beta0.59
1 Month Change0%
3 Month Change7.63%
1 Year Change-86.12%
3 Year Change-94.21%
5 Year Change-97.33%
Change since IPO-94.77%

Recent News & Updates

Recent updates

Analysis Article • Feb 12

We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Jan 10

IGM Biosciences Stock: Bad News With No Turnaround In Sight

Summary IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval, leading to a greater-than-50% drop in share price. Despite holding substantial liquid assets and a collaboration with Sanofi, IGMS currently has no active pipeline candidates, raising concerns about future prospects. With a 73% workforce reduction and no clear direction, IGM Biosciences appears to be burning cash without any near-term developmental biotech activities. Given the lack of pipeline and high downside risk, I maintain a "Sell" rating on IGMS stock, as there's no compelling reason to invest at this time. Read the full article on Seeking Alpha
Analysis Article • Oct 08

We're Not Very Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. Indeed, IGM Biosciences...
Seeking Alpha • Sep 18

IGM Biosciences: Waiting For Godot

Summary Today, we are revisiting with clinical stage biotech concern IGM Biosciences, Inc. for the first time since 2020. IGM Biosciences has a unique approach with IgM antibodies targeting numerous cancer and autoimmune diseases with large potential markets. The company also has a collaboration deal with drug giant Sanofi inked in 2022 and its stock has almost doubled in 2024 year to date. An updated analysis around IGM Biosciences follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • May 12

IGM Biosciences: Unlikely To Move The Needle Again In 2024

Summary IGM Biosciences is developing a different class of antibodies to improve on the classic IgG antibodies. Their most advanced project, aplitabart, is being tested in a clinical trial for metastatic colorectal cancer. The company has a decent cash position but faces risks in the high-risk disease area and uncertainty in its collaboration with Sanofi. Read the full article on Seeking Alpha
Analysis Article • Apr 28

Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Feb 12

IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points

Summary IGM Biosciences, Inc. is conducting phase 1b studies for imvotamab in patients with severe systemic lupus erythematosus and rheumatoid arthritis, with initial results expected in the second half of 2024. The global lupus market is projected to grow to $6.78 billion by 2032 and the global Rheumatoid Arthritis drugs market size is projected to reach $38.61 billion by 2032. Two ongoing studies, one single-arm and one randomized, using Aplitabart for the treatment of patients with 2nd-line metastatic colorectal cancer, expected in the 2nd half of 2024. The global colorectal cancer market is expected to reach $24.08 billion by 2028. Read the full article on Seeking Alpha
Analysis Article • Nov 20

We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • May 10

We're Not Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jan 05

Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Sep 23

IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Aug 29

IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates

BofA Securities has initiated IGM Biosciences (NASDAQ:IGMS) with a buy on advantages the company's IgM antibodies in development have over existing antibody therapies. The firm has a $34 price target on shares (~79% upside based on Monday's close). Analyst Geoff Meacham said that IgM antibodies could have better efficacy compared ot the IgG antibodies used in other therapeutics due to additional binding units that can strongly bind to difficult targets. He noted that IGM's (IGMS) lead candidate, imvotamab, has demonstrated positive phase 1 data in B cell non-Hodgkin’s lymphoma. A separate study of the asset in diffuse large B-cell lymphoma and follicular lymphoma. Meacham added that a relationship with Sanofi (SNY) announced in March could earn the IGM (IGMS) more than $6B in milestone payment and also affirms the company's intellectual property. Seeking Alpha's Quant Rating views IGM as a hold with strong grades for growth and momentum.
Seeking Alpha • Aug 08

IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M

IGM Biosciences press release (NASDAQ:IGMS): Q2 GAAP EPS of -$1.33 misses by $0.93. Revenue of $0.4M. Cash and investments as of June 30, 2022 were $513.2 million, compared to $229.5 million as of December 31, 2021. IGM expects to end 2022 with a balance of approximately $400 million in cash and investments. IGM estimates full year collaboration revenue of approximately $1 million related to the Sanofi agreement. IGM reiterates its previously issued financial guidance expecting full year GAAP operating expenses of $250 million to $260 million including estimated non-cash stock-based compensation expense of approximately $50 million. Shares -1.78%.

Shareholder Returns

IGMSUS BiotechsUS Market
7D0%2.4%1.1%
1Y-86.1%34.6%28.7%

Return vs Industry: IGMS underperformed the US Biotechs industry which returned -4.9% over the past year.

Return vs Market: IGMS underperformed the US Market which returned 19.4% over the past year.

Price Volatility

Is IGMS's price volatile compared to industry and market?
IGMS volatility
IGMS Average Weekly Movement8.0%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

Stable Share Price: IGMS has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: IGMS's weekly volatility has decreased from 16% to 8% over the past year.

About the Company

FoundedEmployeesCEOWebsite
199316Mary Harlerigmbio.com

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

IGM Biosciences, Inc. Fundamentals Summary

How do IGM Biosciences's earnings and revenue compare to its market cap?
IGMS fundamental statistics
Market capUS$76.57m
Earnings (TTM)-US$53.38m
Revenue (TTM)US$145.05m
0.5x
P/S Ratio
-1.4x
P/E Ratio

Is IGMS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IGMS income statement (TTM)
RevenueUS$145.05m
Cost of RevenueUS$150.54m
Gross Profit-US$5.49m
Other ExpensesUS$47.89m
Earnings-US$53.38m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.89
Gross Margin-3.79%
Net Profit Margin-36.80%
Debt/Equity Ratio0%

How did IGMS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/08/15 02:26
End of Day Share Price 2025/08/13 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

IGM Biosciences, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael SchmidtGuggenheim Securities, LLC
Biren AminJefferies LLC
Roger SongJefferies LLC